Archive for the ‘ExL Events News’ Category
An increased volume of data almost always yields more effective machine learning, and for those in drug development, the healthcare sector is the data equivalent of an oil reserve.
The AI Innovations for Life Science and Healthcare Summit, taking place June 13–14 in Philadelphia, will feature a dedicated AI in Life Science track to discuss use cases for machine learning in drug development and clinical trial design.
The use of machine learning in early-stage drug discovery can potentially be applied to optimize initial screening of drug compounds to predicted success rate based on biological factors. This includes R&D discovery technologies like…
The sheer volume of data in the healthcare sector represents a significant opportunity for AI to prove its value. Before a health system invests in systematic computing, ML, or artificial intelligence technologies, providers should have a clear, concrete idea of how they will use these tools to improve care quality, outcomes, or efficiencies.
The AI Innovations for Life Science and Healthcare Summit, taking place June 13–14 in Philadelphia, will feature a dedicated AI in Healthcare track to discuss cases studies where machine learning and AI were employed to improve health outcomes.
Eyal Zimlichman, M.D., Deputy Director, Chief Medical Officer, and Chief Innovation…
It is a distinguished privilege to chair ExL Events’ Pharmacovigilance Audit and Inspections Conference on March 26–27 in Philadelphia. As the conference chairperson, I am eager to welcome you to this benchmark event.
It is my mission to ensure this program equips attendees with skills and practices to adapt and continue to lead the way in complying with global regulations and replicating effective practices in drug safety.
I look forward to learning what lies in store for our work; from new technologies, artificial intelligence, new regulations, and innovative approaches, to ensuring quality and compliance during audits and inspections. To view the full program,
A successful disease awareness campaign will either resonate with patients about the burden of their disease or improve the way HCP educate and engage with their patients around a disease state. Educational and impactful messaging for a successful campaign requires a deep understanding of the patient’s journey and knowledge gaps about a particular disease state.
The Disease Awareness Campaigns Forum, April 4–5, in Philadelphia, will be two days for marketing, communications, and patient/HCP engagement professionals to discuss strategies for building better disease education campaigns. Here are some of the strategies the…
Check out a great article by Applied Clinical Trials, interviewing Kevin Hudziak following his recent presentation at ExL Events’ CROWN on Eli Lilly’s patient engagement initiatives. The interview was conducted by a previous CROWN presenter, Moe Alsumidaie, too!
When asked to explain changing patient behaviors, Husziak said, “Patients and patient communities/advocates are becoming empowered to take a more active role in healthcare, and the digital world is altering the way that people seek healthcare information. Patients are also self-identifying for clinical trials.”
He continued, “They are educated and knowledgeable…
Cytel at the Adaptive Clinical Trials Symposium — Download Complimentary Cytel Whitepaper: Adaptive Trial Accelerates FDA Approval
An average clinical trial can cost $60–80 million. Adaptive design allows a sponsor to modify multiple parts of a trial without incurring additional costs. Using this innovative method will present the opportunity to stipulate collected data at various intervals in order to adjust one or more detailed aspects of the study based on analysis of the data. It is proven that this approach will allow a trial to more efficiently demonstrate the effects of a drug.
Take an in-depth look at how Cytel assisted Napo Pharmaceuticals to optimize an adaptive speed and control to achieve orphan drug exclusivity protection. This…
The Central Monitoring Summit, scheduled for March 22–23 in Philadelphia, has an outstanding list of expert presenters who will deal with the complex issues we must face while exploring the challenges, impacts, and implications of risk-based monitoring. Subjects such as the updated ICH E6 (R2) Guidelines, implementing central monitoring, and the shifting role of a CRA are just some of the topics to be addressed during this meeting. This conference presents an opportunity to examine the present status and future direction of RBM and central monitoring. You can view the full agenda here.
As conference chair of…
Frequently, new formulation approaches end up disappointing the industry because, instead of a breakthrough, they yield slow, incremental development. Is there anything on the horizon that can truly accelerate your drug pipeline? As The Washington Post reports, just a few weeks ago, FDA announced a pilot program to release more detailed study reports from clinical trials. This initiative should quickly provide drug development teams with a much larger library of information about safety and efficacy results to guide their own R&D. How is your company going to take advantage of this new program? Will the drugs you are working…
As the conference chair for MASS East 2018, I would like to invite you to join us in New Brunswick, NJ, on April 9–11 for this innovative and collaborative event. This forum is the ideal meeting place for you and your team members to exchange strategic and operational insights with your industry peers and hear how to optimize the overall quality and effectiveness of your medical operations.
This year’s program hosts a diverse speaking faculty of industry leaders responsible for medical affairs, field activities and Investigator-Initiated Trials. They will offer thought-provoking discussions and actionable solutions for managing medical affairs…
Our friends over at Applied Clinical Trials Online recently shared updates gleaned from attending ExL Events’ January 2018 CROWN Congress with their audience. This article exemplifies the benefits of attending an ExL conference and we thank the publication for sharing this information.
Applied Clinical Trials shared highlights from the Congress, including the following sessions:
CRO MARKET CONSOLIDATION
Evaluating the CRO Industry Consolidation and Predictions for What’s Next
David H. Windley, CFA, CPA, Managing Director, Healthcare Equity Research, JEFFERIES LLC
PATIENT-CENTERED DIGITAL RECRUITMENT
Creating a Digital Patient Recruitment Ecosystem Focused on Patients to Optimize Engagement
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs